Panbela Therapeutics Q4 2023 GAAP EPS $(65.90) Misses $(24.34) Estimate
Portfolio Pulse from Benzinga Newsdesk
Panbela Therapeutics (NASDAQ:PBLA) reported a Q4 2023 GAAP EPS loss of $(65.90), significantly missing the analyst consensus estimate of $(24.34) by 170.75%.
March 26, 2024 | 8:51 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Panbela Therapeutics reported a Q4 2023 GAAP EPS loss of $(65.90), missing the consensus estimate of $(24.34) by 170.75%.
The significant miss in earnings per share (EPS) compared to analyst expectations usually leads to negative investor sentiment in the short term. Given the magnitude of the miss (170.75%), this is likely to have a pronounced negative impact on the stock price as it reflects operational challenges or unexpected costs that were not priced into the stock.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100